Distribution of therapeutic procedures and use of drug therapies in patients with angiographically confirmed coronary artery diseases

Anadolu Kardiyoloji Dergisi

Volumn 2, Issue 1, 2002, Pages 18-23

  Sönmez, Kenan ^a   Akçay, Ahmet ^a   Akçakoyun, Mustafa ^a   Demir, Durmuş ^a   Elönü, Orhan Hakan ^a   Onat, Özgür ^a   Duran, Nilüfer Ekşi ^a   Gençbay, Murat ^a   Deǧertekin, Muzaffer ^a   Turan, Fikret ^a  

^a NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EUROPE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; EPIDEMIOLOGY; MIDDLE AGED; RADIOGRAPHY; STATISTICS; TURKEY (REPUBLIC); UTILIZATION REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; EUROPE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RISK FACTORS; TURKEY;

EID: 0008984012     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. CHD prevention in clinical practice
2. Evidence of effectiveness of interventions for secondary prevention and treatment of coronary heart disease in primary care
3. Long-term effect on mortality of stopping smoking after unstable angina and myocardial infarction
4. Clinical trials of hypertension treatment: Implications for subgroups
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
6. The effect of pravastatin in coronary events after myocardial infarction in patients with average cholesterol levels
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Collaborative overview of randomised trials of antiplatelet therapy. 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
9. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association
10. Overview of randomised clinical trials in heart disease. 1. Treatments following myocardial infarction
11. Beta blockade during and after myocardial infarction: An overview of the randomized trials
12. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials
13. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular enlargement trial. The SAVE Investigators
14. Türk Kardiyolji Derneǧi'nce Hazirlanan Koroner Arter Hastaliǧi Yaklaşim ve Tedavi Kilavuzu
15. Prevention of coronary heart disease in clinical practice
16. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention
17. Optimal risk factor management in the patient after coronary revascularization. A statement for health-care professionals from an American Heart Association Writing Group
18. A British cardiac society survey of the potential for the secondary prevention of coronary heart disease: Principal results
19. Evolution long-terme de la prescription médicamenteuse chez 174 patients attients d'infarctus du myocarde suivis pendant 4.5 ans (étude DEVENIR)
20. A European Society of Cardiology survey on secondary prevention of coronary heart disease: Principal results
21. Treatment of hypercholesterolemia at discharge from hospital after acute myocardial infarction in a coronary heart disease low incidence area: Galicia (Northwest of Spain)
22. The Treatment gap in coronary artery disease and heart failure: Community standards and the post discharge patient
23. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme
24. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
25. Secondary prevention of myocardial infarction in Spain
26. After 4S, CARE, and LIPID- is evidence-based medicine being practised?
27. The impact of landmark clinical trials on secondary prevention acute myocardial infarction (AMI) in Spain
28. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events